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Non-cystic fibrosis (non-CF) bronchiectasis is 
a pathological condition characterized by in-
flamed, dilated, and thick-walled bronchi. Con-
ditions predisposing to bronchiectasis include 
host immune defects, post-infective sequelae, and 
defects in mucociliary clearance (Pasteur et al., 
2000), although in most cases no cause can be 
found. Bronchiectasis is notable for chronic 
sputum production, recurrent lower respiratory 
tract infections, and persistent bacterial coloni-
zation. Such patients frequently undergo a vi-
cious cycle of events: failure to clear bacterial 
infections followed by inflammatory responses 
that further impair host defenses and mucociliary 
clearance, resulting in chronic inflammation that 
in turn leads to persistent bacterial colonization 
(Whitters and Stockley, 2012). Pseudomonas aer-
uginosa is isolated in up to 30% of adult patients 
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Although specific antibody induced by pathogens or vaccines is a key component of protec-
tion against infectious threats, some viruses, such as dengue, induce antibody that en-
hances the development of infection. In contrast, antibody-dependent enhancement of 
bacterial infection is largely unrecognized. Here, we demonstrate that in a significant 
portion of patients with bronchiectasis and Pseudomonas aeruginosa lung infection, anti-
body can protect the bacterium from complement-mediated killing. Strains that resist 
antibody-induced, complement-mediated killing produce lipopolysaccharide containing 
O-antigen. The inhibition of antibody-mediated killing is caused by excess production of 
O-antigen–specific IgG2 antibodies. Depletion of IgG2 to O-antigen restores the ability 
of sera to kill strains with long-chain O-antigen. Patients with impaired serum-mediated 
killing of P. aeruginosa by IgG2 have poorer respiratory function than infected patients who 
do not produce inhibitory antibody. We suggest that excessive binding of IgG2 to O-antigen 
shields the bacterium from other antibodies that can induce complement-mediated 
killing of bacteria. As there is significant sharing of O-antigen structure between different 
Gram-negative bacteria, this IgG2-mediated impairment of killing may operate in other 
Gram-negative infections. These findings have marked implications for our understanding 
of protection generated by natural infection and for the design of vaccines, which should 
avoid inducing such blocking antibodies.
© 2014 Wells et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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with bronchiectasis (Pasteur et al., 2010) and is a risk factor 
for declining lung function (Martínez-García et al., 2007); it 
is also associated with reduced quality of life and a poorer prog-
nosis (Wilson et al., 1997; Martínez-García et al., 2005; Bilton, 
2008). Once established, it is difficult to eradicate and is often 
resistant to numerous antibiotics, making routine manage-
ment less effective. Therefore, understanding both the infecting 
bacterium and the response to the infection is vital to combat 
this disease.
Examination of the literature reveals a single report of a 
patient with bronchiectasis with impaired serum-killing of 
P. aeruginosa who died despite treatment (Waisbren and Brown, 
1966). We hypothesized that similar impaired serum-killing 
also exists for other bronchiectasis patients with chronic Pseu-
domonas infections and that this contributes to disease severity. 
Indeed, IgG antibody to P. aeruginosa and complement com-
ponents are readily detectable in the serum and sputum of 
patients with bronchiectasis (Hill et al., 1998), and these fac-
tors are known to opsonize colonizing P. aeruginosa in the 
lung (Hann and Holsclaw, 1976; Hill et al., 1998). Thus, it is 
highly likely that antibody-mediated killing is involved in the 
host defense against bacterial lung infection. Here, we sought 
to establish if impaired serum killing is a common phenome-
non in patients with bronchiectasis and to elucidate the 
mechanism underpinning a lack of serum bactericidal activity. 
In addition, we sought to identify if the lack of serum bacteri-
cidal activity in patients had a correlation with disease severity.
RESULTS
Impaired serum killing in bronchiectasis patients
Historical data associated impaired serum-killing of P. aerugi-
nosa with poor outcome in a patient with bronchiectasis 
(Waisbren and Brown, 1966). To explore if this is an isolated 
event or a more general phenomenon, we examined the serum 
sensitivity of P. aeruginosa isolates taken from 11 different pa-
tients with bronchiectasis and chronic Pseudomonas infection 
(Table 1). Serum was collected from each patient and 20 healthy 
individuals. Each patient (P) and their isolated bacterium (B) 
and serum (S) were assigned the same number; patient P1, 
with serum S1, is colonized by P. aeruginosa B1. We found that 
eight patients had serum (S4–11) that could kill their cognate 
colonizing strain (B4-11), but three patients had serum (S1–3) 
Table 1. Disease severity of bronchiectasis patients, with or 
without IgG2 blocking factor
Patient ID Colonized with P. 
aeruginosa?
Serum ID Does serum 
mixed with 
HCS kill B1
FEV1% 
predicted
Impaired serum killing, P. aeruginosa colonized
P1 Yes- B1 S1 No 28
P2 Yes- B2 S2 No 66
P3 Yes- B3 S3 No 26
PN1 Yes- BN1 SN1 No 17
PN2 Yes- BN2 SN2 No 37
PN3 Yes- BN3 SN3 No 31
Normal killing, P. aeruginosa colonized
P4 Yes- B4 S4 Yes 105
P5 Yes- B5 S5 Yes 78
P6 Yes- B6 S6 Yes 97
P7 Yes- B7 S7 Yes 43
P8 Yes- B8 S8 Yes 59
P9 Yes- B9 S9 Yes 64
P10 Yes- B10 S10 Yes 90
P11 Yes- B11 S11 Yes 68
PN4 Yes- BN4 SN4 Yes 61
PN5 Yes- BN5 SN5 Yes 52
PN6 Yes- BN6 SN6 Yes 67
PN7 Yes- BN7 SN7 Yes 85
PN8 Yes- BN8 SN8 Yes 42
PN9 Yes- BN9 SN9 Yes 93
PN10 Yes- BN10 SN10 Yes 65
PN11 Yes- BN11 SN11 Yes 54
PN12 Yes- BN12 SN12 Yes 43
PN13 Yes- BN13 SN13 Yes 48
PN14 Yes- BN14 SN14 Yes 75
PN15 Yes- BN15 SN15 Yes 101
PN16 Yes- BN16 SN16 Yes 58
PN17 Yes- BN17 SN17 Yes 32
Normal killing, Not colonized by P. aeruginosa
PN18 No SN18 Yes 46
PN19 No SN19 Yes 70
PN20 No SN20 Yes 35
PN21 No SN21 Yes 46
PN22 No SN22 Yes 52
PN23 No SN23 Yes 78
PN24 No SN24 Yes 22
PN25 No SN25 Yes 54
PN26 No SN26 Yes 63
PN27 No SN27 Yes 69
PN28 No SN28 Yes 62
PN29 No SN29 Yes 23
PN30 No SN30 Yes 58
Patients with cystic fibrosis and P. aeruginosa
CF1 Yes SCF1 Yes NDa
CF2 Yes SCF2 No ND
CF3 Yes SCF3 Yes ND
aNot determined.
Table 1. Disease severity of bronchiectasis patients, with or 
without IgG2 blocking factor (Continued)
Patient ID Colonized with P. 
aeruginosa?
Serum ID Does serum 
mixed with 
HCS kill B1
FEV1% 
predicted
CF4 Yes SCF4 Yes ND
CF5 Yes SCF5 Yes ND
CF6 Yes SCF6 No ND
CF7 Yes SCF7 Yes ND
CF8 Yes SCF8 Yes ND
aNot determined.
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isolated from patients with bronchiectasis from a geographi-
cally distinct cohort who were colonized with P. aeruginosa 
(Table 1). Three sera (SN1–3) failed to kill strain B1 but could 
kill strain B4, whereas the remainder (SN4–17) could affect 
serum-mediated killing of both B1 and B4 (Table 1 and Fig. 1, 
E and F). A similar phenomenon was observed for a small 
sample of patients with cystic fibrosis (Table 1). Thus, 20% 
of the patients with bronchiectasis and P. aeruginosa infection 
had impaired serum killing of their strains, and the factor in-
volved appeared to be specific both to the patient sera and the 
infecting P. aeruginosa strain.
Impaired serum contains a blocking factor
We next explored whether the impaired serum killing results 
from an inhibitory factor present within the serum or from 
the lack of a serum component required for bactericidal activ-
ity. Specific anti–P. aeruginosa IgG, IgA, and IgM were present 
that failed to kill their infecting strains (B1–3; Fig. 1 A). The 
bactericidal activity of the eight sera (S4–11) was inactivated 
by heat treatment, implying that serum killing was caused by 
the action of complement (unpublished data). The strains 
from patients with impaired bacterial killing were not innately 
resistant to killing, as sera from 20 healthy human controls 
(HCS) and sera from patients with bronchiectasis but without 
P. aeruginosa colonization (SN18–30) killed these three strains 
within 45 min (Fig. 1 B). Similar results were found for B2 
and B3 (unpublished data).
Next, we tested each patient’s serum against all 11 of the 
P. aeruginosa isolates. We found that S1–3 could not kill B1–3 
but could kill the P. aeruginosa strains from the other 8 patients 
(Fig. 1 C). In contrast, S4–11 could kill B1–3 (Fig. 1 D). This 
suggests the factors mediating resistance to serum killing are 
common to B1–3 and S1–3 but absent from the other strains 
and sera. We extended this analysis by testing sera (SN1–17) 
Figure 1. Identification of patients with impaired serum killing. (A) Killing curves of P. aeruginosa strains isolated from bronchiectasis patients 
with their autologous serum at 45, 90, and 180 min. Negative values correspond with a decrease in viable P. aeruginosa compared with initial concentra-
tion. (B) Killing of B1 by sera taken from 20 healthy people at 45, 90, and 180 min. Killing of B1 by sera from patients with bronchiectasis but without 
P. aeruginosa colonization (SN18–SN30) is also shown. The curves depicting killing by HCS1-HCS20 and SN18-SN30 are overlaid to simplify. (C) Killing 
curves of all strains (B1–B11) by serum (S1). (D) Killing curves of P. aeruginosa strain B1 by patient serum (S1–S11). (E) Killing curves of B1 and B4 by sera 
SN1, 2, and 3 (SN1–3). (F) Killing curves of B1 and B4 by sera SN4–SN17. The curves depicting killing by SN4–SN17 are overlaid to simplify graphs. For all 
serum bactericidal assays, error bars represent the mean ± SD for a minimum of three independent experiments.
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serum. To identify the inhibitor, S1 was fractionated, based on 
molecular weight, and fractions were added to HCS. Inhibi-
tion was observed when the 100–300-kD fraction was added 
to HCS (Fig. 3 A). As this fraction contains IgG antibody, we 
investigated whether depleting antibody could restore bacte-
ricidal activity. Antibody was depleted by passing S1 over ei-
ther a Protein A or a Protein G column, reducing total IgG 
titers 100-fold (Fig. 3 B). We found that the inhibitory 
serum S1, when depleted of antibody using either a Protein A 
or G column, could kill B1 within 180 min. Moreover, when 
mixed with HCS (50:50), B1 was rapidly killed indicating that 
the antibody-depleted serum no longer had the capacity to 
inhibit the bactericidal activity of HCS (Fig. 3 C). Importantly, 
antibodies eluted from the Protein A and G columns, in a 
volume equal to that of S1 originally applied to the column, in-
hibited the bactericidal activity of HCS, even when added at 
low concentrations (4–6%; Fig. 3 D). Similar observations were 
made for S2 and S3 (unpublished data). Due to the different 
antibody binding affinities of Protein A and G (Table S1), these 
findings suggest IgG is the blocking factor present in S1–3.
IgG2 is the inhibitory factor in impaired serum
All of the initial cohort of 11 patients had normal proportions of 
the four IgG subclasses overall (Table 2); however, to determine 
in the sera with impaired capacity to kill, at levels comparable 
to or greater than those in HCS that killed all the bacterial 
isolates (Fig. 2 A). Furthermore, IgG and complement com-
ponents C1q, C3, and the C5b-9 membrane attack complex 
(MAC) were deposited on all strains (Fig. 2, A and B). Antibody 
binding and complement deposition were confirmed by im-
munofluorescence microscopy (unpublished data). Thus, the 
impaired serum killing is not due to a lack of complement or 
antibody binding.
To determine if the lack of bacterial killing was due to a 
blocking factor in the serum, we mixed serum with impaired 
killing with HCS. Addition of HCS to S1–3 (50:50) did not 
restore serum killing, whereas HCS similarly diluted with PBS 
readily killed P. aeruginosa (Fig. 2 C). These data suggest that 
impaired serum-killing by S1–3 is caused by the presence of a 
factor inhibiting serum-mediated killing. In fact, complete 
killing by S1–3 was only restored when HCS represented 94, 
70, and 80%, respectively, of the mixed sera (Fig. 2 D), indicat-
ing the patients serum had a potent capacity to inhibit killing.
IgG blocks the ability for serum to kill specific  
Pseudomonas strains
We established that the impaired serum killing of patients’ 
cognate Pseudomonas strains is due to a blocking factor in their 
Figure 2. Impaired serum is caused by a blocking factor, not a lack of antibody or complement. (A) Binding of specific IgG, IgM, IgA antibodies 
and C1q and C3 complement factors from indicated patient serum to B1, B2, and B3. Each strain was tested with autologous serum and at least three 
separate healthy controls. Data are representative of three independent experiments. (B) Serum titers of P. aeruginosa–specific IgG compared with C5b-9 
MAC deposition on autologous strains. (C) Inhibition of HCS-mediated killing of strains B1–3 with a 50:50 mix of HCS and autologous patient sera (S1–3). 
Dashed lines represent HCS mixed 50:50 with buffer. (D) Killing of P. aeruginosa strains B1–3 at 180 min by mixed sera consisting of different percent-
ages of HCS mixed with autologous serum. For all data, error bars represent the mean ± SD for a minimum of three independent experiments.
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LPS is the target of the inhibitory IgG2
To determine if the inhibitory IgG2 antibody targeted a spe-
cific bacterial factor, we performed Western immunoblotting 
of outer membrane protein and polysaccharide fractions with 
patient serum and anti–human IgG. S1 contained antibodies 
that recognized proteins from all strains (Fig. 5 A). In contrast, 
the serum only recognized the O-antigen side chains of LPS 
from B1–3 and did not recognize O-antigen of strains from 
patients without impaired serum killing (Fig. 5 B). Similar results 
were obtained for S2 and S3, whereas HCS had no detectable 
anti–O-antigen antibody to B1–3 (Fig. 5 C). SDS-PAGE and 
silver staining of LPS fractions revealed that the strains B1, B2, 
and B3 produced significant amounts of long-chain O-antigen 
but the other strains did not (Fig. 5 D).
By binding the LPS isolated from B1 to an ELISA plate we 
determined that the patients with impaired serum-mediated 
if a specific IgG isotype could be responsible for the impaired 
killing of bacteria by serum seen in 3 patients, the titer of each 
IgG sub-class specific for P. aeruginosa was determined. Anti– 
P. aeruginosa IgG1 titers were not statistically different between 
impaired and normal killing sera groups (Fig. 4 A), and nei-
ther were levels of IgG3 and IgG4 (not depicted). In contrast, 
S1–3 had significantly (P < 0.001) increased titers of anti– 
P. aeruginosa IgG2 compared with sera displaying normal bac-
tericidal activity (Fig. 4 A). To test if IgG2 is the inhibitory 
factor, we purified IgG2 from S1 by passing the serum over an 
affinity column coated with a monoclonal antibody against 
human IgG2 (Jefferis et al., 1992). The IgG2-depleted flow-
through lost its inhibitory capacity. In contradistinction, IgG2 
eluted from the column, in the same volume of serum loaded 
on the column, blocked the serum bactericidal activity of 
HCS (Fig. 4 B).
Figure 3. IgG inhibits serum-mediated killing. (A) Killing of B1 by HCS mixed 50:50 with S1 and HCS fractionated into indicated size ranges. The 
killing curves for several fractions overlap and have been separated to allow for visualization. Data are representative of three independent experiments. 
(B) Titer of total IgG1 and IgG2 of S1 serum before and after passing through Protein A and G columns. Data are representative of two independent ex-
periments. (C) Killing curves of P. aeruginosa strain B1 by serum S1. Killing was measured for S1 depleted of antibody using a Protein G column, before 
and after addition of HCS (50:50). Data are representative of three independent experiments. (D) IgG purified from S1 using a Protein G column was re-
suspended in PBS to the same volume of serum loaded on the column. Purified IgG was added to HCS in indicated concentrations and measured for its 
ability to kill B1 at 45, 90, and 180 min. Data are representative of three independent experiments. Error bars represent the mean ± SD.
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observations suggest the long-chain O-antigen of LPS is 
the target of inhibitory antibody. To test this, LPS purified 
from B1 was immobilized on a polymyxin-B agarose column 
and S1 was passed through the column to remove antibody 
specific to the LPS (Fig. 6 A). The recovered flow-through 
fraction was now able to kill B1 and no longer inhibited the 
killing activity of HCS (Fig. 6 B). Conversely, anti-LPS 
antibody eluted from the column inhibited the bacteri-
cidal activity of HCS in a dose-dependent manner (Fig. 6, 
A and C). Immunofluorescence microscopy revealed that the 
flow-through fraction lacked detectable anti–P. aeruginosa 
IgG2 (unpublished data). In contrast, anti–P. aeruginosa IgG1 
remained detectable in the serum depleted of anti-LPS anti-
body (Fig. 6 A).
bacterial killing had high levels of anti-LPS IgG by ELISA 
(Fig. 5 E). To test if the level of anti-LPS antibody is responsi-
ble for this effect, rather than simply the presence of anti-LPS 
antibodies per se, we purified anti-LPS antibodies from S4, a 
serum that has normal bactericidal activity. The eluted anti-
bodies, concentrated 10-fold on the column (Fig. 5 F), inhibited 
the bactericidal activity of HCS in a dose-dependent manner 
(Fig. 5 G), indicating the titer of anti-LPS antibody in serum 
is critical for inhibition.
Antibodies against O-antigen, but not  
lipid A or core, inhibit serum killing
The three strains that could not be killed by serum containing 
blocking IgG2 possessed high amounts of O-antigen. These 
Figure 4. IgG2 inhibits serum-mediated killing. (A) Titers of IgG1 and IgG2 isotypes in patient serum and HCS that is specific to infecting strains. 
Dashed line indicates the median IgG2 titer from sera S4–S11. Data are representative of three independent experiments. ***, P < 0.001. (B) Killing of B1 
was measured with S1 depleted of IgG2 mixed with HCS or with a mixture HCS supplemented with IgG2 purified from S1 or HCS alone. For all data, error 
bars represent the mean ± SD for a minimum of three independent experiments.
Table 2. Total antibody titers of bronchiectasis patients
Patient IgG IgA IgM
P1 10.73 2.2 1.07
P2 12.66 2.17 0.82
P3 10.69 4.49 1.05
P4 11.81 4.06 1.29
P5 11.18 1.51 4.19
P6 11.91 3.4 1.64
P7 16.64 10.37a 0.73
P8 15.6 3 3.08
P9 14.5 3.59 1.15
P10 13.89 2.78 0.99
P11 12.5 1.87 0.77
Normal range 6.0–16.00 0.8–4.0 0.50–2.00
aNo paraprotein detected by IMFIX.
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in the lungs of patients suffering from bronchiectasis (Hill et al., 
1998). We hypothesized that patients with impaired immunity 
and P. aeruginosa colonization would have high titers of IgG2 
present in the lung. To confirm this, the sol phase of sputum 
from P2 (impaired killing) and P4 (normal killing) was har-
vested and the levels of IgG1 and IgG2 were measured. P2 sol 
phase sputum had 512 and 220 mg/liter IgG1 and IgG2, re-
spectively, whereas P4 sol phase contained 315 mg/liter IgG1 
and 158 mg/liter IgG2.
Having demonstrated the presence of antibody in the lung, 
we next sought to determine whether this antibody played 
a role in protecting bacteria from serum-mediated killing 
in vivo. To establish this, we first investigated whether P. aeruginosa 
was opsonized by antibody in vivo. Immunofluorescence mi-
croscopy of sputum smears revealed bacteria present within the 
sputum were labeled with anti–human IgG2-FITC (Fig. 7 A). 
Additional investigations revealed cultured bacteria could also 
be labeled with IgG2 when opsonized with 1:200 sol phase 
sputum (Fig. 7 A). To confirm that this opsonization protects 
All P. aeruginosa strains contain lipid A and core oligosac-
charide of LPS. Consequently, we depleted S1 of antibody to 
lipid A and the core elements by passing S1 over a polymyxin B 
column on which LPS isolated from B4, which lacks O-antigen, 
was immobilized (Fig. 6 A). The flow-through antibody had 
a 30-fold lower level of binding to lipid A and core oligo-
saccharide compared with both the native serum and the 
antibody eluted from the column (Fig. 6 A). However, the 
flow through from this column still recognized O-antigen–
containing LPS purified from B1 at a level similar to native S1 
(Fig. 6 A). This flow-through inhibited the killing of B1 by 
HCS, but the antibody recognizing lipid A and core oligosac-
charide eluted from the column did not (Fig. 6 D). These data 
are summarized in Fig. S1.
The role of inhibitory antibodies in the lung
The role of serum-mediated killing in controlling bacterial 
growth during lung infection is not widely recognized. However, 
previously high levels of antibody were shown to be present 
Figure 5. Inhibitory antibody recognizes P. aeruginosa LPS and is dose dependent. (A) Western blot of outer membrane protein fractions obtained 
from B1–B11 probed with S1 as a primary antibody and anti–human IgG as the secondary antibody. (B) Polysaccharide-only preparations from P. aerugi-
nosa isolates analyzed by Western blot probed with S1 serum as a primary antibody and anti-IgG as a secondary antibody. (C) Western blot of LPS puri-
fied from B1, B2, and B3 probed with S2, S3, or HCS as the primary antibody and anti–human IgG as the secondary antibody. S2 and S3 have high 
LPS-specific IgG response. In contrast, no anti-LPS IgG is detected in HCS. All Western blots (A–C) are representative of three independent experiments. 
(D) Polysaccharide-only preparations from P. aeruginosa isolates are analyzed by silver stain. Data are representative of six independent experiments. 
(E) Patient serum IgG titer specific for LPS isolated from B1 determined by ELISA. LPS was isolated from P. aeruginosa strain B1 and attached to a 96-well 
plate. ELISA was performed with dilutions of patient or healthy sera and anti–human IgG conjugated to alkaline phosphatase. Error bars represent mean 
± SD for three independent experiments. (F) Antibodies specific for B1 LPS were purified and concentrated from S4. S1 and anti-LPS antibodies concen-
trated from S4 were used as primary antibodies in a Western blot against B1 LPS. Data represents three independent experiments. (G) Killing curve of B1 
with anti-LPS antibodies concentrated from S4 mixed with HCS. HCS serum similarly diluted with buffer is used as a control. Error bars represent mean ± 
SD for three independent experiments.
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with either HCS or S1 led to rapid killing of the bacteria. In 
contrast, B1 opsonized with S1 was not killed (Fig. 7 C).
These data suggest an important role for inhibitory anti-
body in protecting bacteria within the lung from immune-
mediated clearance. However, it is accepted that P. aeruginosa 
resides in a biofilm within the lung. Therefore, we investigated 
the effect of serum on an established biofilm. B1 forms a thick 
biofilm in a 96-well plate over 24 h. Incubation of the B1 
biofilm with HCS and S4 sera for 2 h drastically reduced the 
amount of biofilm. In contrast, S1 had no effect on the 
amount of biofilm over a similar period (Fig. 7 D).
Patients with inhibitory antibodies have worse lung function
The results of the aforementioned in vivo and in vitro studies 
suggest that the presence of inhibitory antibody may have clin-
ical relevance. Thus, we sought to determine whether patients 
with bronchiectasis and inhibitory levels of anti-LPS IgG2 
bacteria from complement-dependent killing, we explored 
whether HCS could kill bacteria from sputum. The unfiltered 
sol phase of sputum from P2, containing opsonized bacteria, 
was mixed 50:50 with HCS; however, there was no reduction 
in bacterial numbers over 180 min of incubation (Fig. 7 B). To 
confirm this phenomenon, B1 was incubated with a mixture 
of HCS and sterile sol-phase from P2. No complement- 
dependent killing was observed over 180 min. In contrast, B1 
incubated with a mixture of HCS and sterile sol-phase from 
P4 was rapidly killed within 45 min (Fig. 7 B).
Opsonization is important for cell-mediated killing, which 
is known to play a vital protective role within the lung (Whitters 
and Stockley, 2012). We hypothesized that inhibitory antibod-
ies may also play a role in cell-mediated killing. Thus, we in-
vestigated killing of B1 and B4 by washed peripheral blood 
cells. B1 opsonized with HCS was rapidly killed on incuba-
tion with peripheral blood cells. Similarly, opsonization of B4 
Figure 6. Inhibitory antibodies are specific for the O-antigen. (A) Schematic of treatment of S1 serum and resultant IgG titers specific to LPS puri-
fied from either B1 (with O-antigen) or B4 (without O-antigen). S1 titers against the two LPS extracts are measured after no treatment, passage through, 
or elution from a column containing purified B1 LPS or passage through or elution from a column containing B4 LPS. In each case, all column fractions 
were resuspended in PBS to the same volume of serum added to the column. (B) Killing curve of P. aeruginosa B1 treated with S1 or S1:HCS (50:50) de-
pleted of anti-LPS antibodies. (C) Killing curve of B1 after incubation with anti-LPS antibodies purified from S1 and mixed with HCS at different concen-
trations. (D) Killing curve of P. aeruginosa B1 treated with HCS mixed with either S1 depleted of antibodies to the lipid A and core oligosaccharides of LPS 
or antibodies that recognize lipid A and core oligosaccharide. For all data, error bars represent the mean ± SD of three independent experiments.
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(Halstead et al., 2010). In the case of dengue fever, circulating 
antibodies bind to the newly infecting virus but do not neu-
tralize infection. Instead, these antibodies enhance viral entry 
via efficient interaction of the virus–antibody complex with 
Fc receptors (Halstead et al., 2010; Flipse et al., 2013). How-
ever, the action of antibody in exacerbating bacterial infec-
tious disease is less well understood. Our results indicate that 
in patients with bronchiectasis, who are chronically colonized 
with P. aeruginosa, the presence of high titers of IgG2 antibod-
ies specific for the O-antigen of LPS impairs serum-mediated 
killing of the infecting strain and is associated with a poorer 
lung function. Here, we describe antibody-dependent en-
hancement of bacterial infection and demonstrate the mech-
anism is different to that for dengue.
Lack of serum bactericidal activity against P. aeruginosa has 
previously been noted for patients with CF (Waisbren and 
Brown, 1966; Guttman and Waisbren, 1975). Moreover, increased 
anti-LPS antibody titers have been noted in CF patients chron-
ically infected with P. aeruginosa (Fick et al., 1986). Separately, 
high levels of IgG3 and IgG2 specific for lipid A and O-antigen 
were shown to correlate with deteriorating pulmonary function 
antibody had more marked disease severity than those patients 
whose serum could mediate killing. We used forced expiratory 
volume in 1 s (FEV1) as a measure of lung function. Individuals 
colonized with P. aeruginosa who also possessed inhibitory an-
tibody had poorer lung function when compared with indi-
viduals colonized with P. aeruginosa whose serum displayed 
normal killing (P < 0.002) and patients with bronchiectasis 
who were not colonized with P. aeruginosa (P < 0.05; Fig. 8 A 
and Table 1). This indicates the impaired capacity to kill bacteria 
has clinical consequences. Interestingly, a similar proportion 
of patients from two different cohorts displayed IgG2-mediated 
inhibition of serum killing, suggesting there may be an un-
derlying genetic, rather than acquired, basis for an elevated 
response (Table 1).
DISCUSSION
Antibody is usually associated with protection against infec-
tious disease. In contrast, antibody-dependent enhancement 
of infection is seen for some microbial organisms, most nota-
bly viruses such as dengue fever (Halstead and O’Rourke, 1977), 
but to a lesser extent parasitic organisms such as leishmaniasis 
Figure 7. Significance of inhibitory antibodies in vivo. (A) Immunofluorescence labeling of bacteria present in sputum with anti–human IgG2-FITC 
(top left). Immunofluorescence labeling of cultured B1 bacteria with sol-phase sputum (top middle) or patient serum (top right) used as the source of 
primary antibody and anti–human IgG2-FITC. Bottom images are corresponding light images. Bar, 2 µm. (B) Killing curves for bacteria already present in 
P2 sputum after mixing the unfiltered sol phase with HCS 50:50. Killing curves for B1 with a 40:60 mix of HCS and sterile sol phase sputum isolated from 
either P2 or P4 are also shown. Error bars represent the mean ± SD of three independent experiments. (C) Killing curves for B1 or B4 by washed peripheral 
blood cells after 20-min opsonization with a 1/10 dilution of HCS, S1, or S4. Negative values correspond with a decrease in viable P. aeruginosa compared 
with initial concentration. Error bars represent the mean ± SD of three independent experiments. (D) Biofilm formation of B1 after overnight growth fol-
lowed by no treatment or exposure to HCS, S1, or S4 serum for 2 h. Biofilm formation was examined in polystyrene microtiter plates. Error bars represent 
the mean ± SD of 16 independent experiments. **, P < 0.01.
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protective antibodies (Taborda et al., 2003). Notably, in the 
Salmonella study, although IgG was found to be inhibitory in 
the serum, the specific isotype conferring inhibition was not 
identified. Furthermore, in the current study, the impaired 
serum killing is not associated with HIV infection or an im-
munocompromised state.
Our findings have significant implications for vaccine de-
sign. Currently, LPS is thought to be an optimal target for pro-
tective antibodies. Three O-antigen–based vaccines against 
P. aeruginosa, Pseudogen, PEV-01, and Aerugen, have reached 
phase II or III trials (Pennington et al., 1975; Langford and 
Hiller, 1984; Cryz et al., 1997). However, two vaccines resulted 
in worse clinical status in the vaccinated group and the third 
trial was suspended (Cryz et al., 1989; Döring and Pier, 2008). 
These studies have not detailed the IgG subclasses induced in 
response to the vaccine. The current study provides a poten-
tial mechanistic basis for the failure of these vaccines strate-
gies. It indicates that candidate O-antigen polysaccharide-based 
vaccines may elicit imbalanced anti–O-antigen (IgG2 domi-
nant) antibody induction, rendering the vaccine ineffective 
while increasing the susceptibility to life-threatening P. aerugi-
nosa infections. Furthermore, historical reports of the associa-
tion of impaired serum killing with other bacterial infections 
suggest this mechanism may be common for a wide variety of 
Gram-negative bacterial infections (Waisbren and Brown, 1966). 
Importantly, understanding the impact elevated levels of IgG2 
have on infections could provide opportunities to attenuate 
disease in several clinical settings.
MATERIALS AND METHODS
Patient details, strains, and samples. Bronchiectasis patients with and 
without chronic P. aeruginosa colonization were identified and confirmed by 
CT scan. Eleven bronchiectasis patients with chronic P. aeruginosa colonization 
were identified. P. aeruginosa was isolated by sputum culture on chocolate blood 
agar and Pseudomonas isolation agar and subsequently cultured in Luria broth. 
Serum was collected from each patient and 20 healthy individuals. Each patient 
(P), their isolated bacterium (B), and serum (S) were assigned the same num-
ber; patient P1, with serum S1, is colonized by P. aeruginosa B1 (Table 1). In the 
absence of a widely recognized disease severity index in bronchiectasis, the 
degree of lung function impairment was evaluated using forced expiratory 
volume in 1 s (FEV1) as a percent predicted of a normal FEV1. This work was 
performed in compliance with the human ethical approval guidelines granted 
by the Birmingham Ethics Committee (code RRK3404) and Newcastle and 
North Tyneside Research Ethics committee (code 12/NE/0248). Additional 
serum samples were obtained from patients with bronchiectasis regardless of 
whether they had P. aeruginosa colonization or not. These samples were from a 
distinct geographical location (Newcastle) and each patient (PN), their isolated 
P. aeruginosa if present (BN), and serum (SN) were assigned the same number. 
Serum samples from eight patients with cystic fibrosis (SCF) and Pseudomonas 
colonization were from Birmingham. Colonization was defined by positive 
P. aeruginosa culture from sputum on at least two separate occasions.
Analysis and manipulation of serum. Serum bactericidal assays were 
performed in triplicate using a modification of the method described 
MacLennan et al. (2010). In brief, bacteria were grown overnight in 5 ml of 
LB at 37°C and resuspended in PBS to a final concentration of 107 CFU/ml; 
10 µl was then mixed with 90 µl of undiluted human serum at 37°C with shak-
ing (180 rpm), and viable counts were determined. Serum mixing experiments 
were performed by first mixing the serum with either PBS, concentrated an-
tibodies, other sera, unfiltered sol phase of sputum or sterile sol phase of 
(Kronborg et al., 1993). In contrast, our data demonstrate that 
in bronchiectasis patients, high titers of IgG2 specific for the 
O-antigen of LPS are sufficient to impair serum-mediated 
killing of P. aeruginosa. Importantly, high titers of IgG2 in the 
sputum are associated with phenotypes within the lung, in-
cluding opsonization of infecting bacteria, inhibition of cell-
mediated killing, and lack of biofilm clearance.
The biological properties of IgG2 may be a factor in its 
role as an inhibitor of serum- and/or cell-mediated killing. 
Switching to IgG2 is particularly associated with responses to 
bacterial polysaccharides (Siber et al., 1980) but, in contrast to 
IgG1 and IgG3, the C1q-binding sites on IgG2 are frequently 
not exposed on antigen binding (Brüggemann et al., 1987; 
Schroeder and Cavacini, 2010). IgG2 also binds to only one 
class of FcR (FcRII), whereas other IgG classes bind mul-
tiple classes (Normansell, 1987; Schroeder and Cavacini, 2010). 
Indeed, IgG2 antibodies have been seen to exert antiphago-
cytic effects on P. aeruginosa (Hornick and Fick, 1990). How-
ever, we hypothesize that anti–O-antigen IgG2 inhibits killing 
of the P. aeruginosa strains by a mechanism similar to that re-
cently described for nontyphoidal Salmonella enterica infection 
in some HIV-infected Malawian adults (MacLennan et al., 2010). 
Thus, inhibitory IgG2 antibodies bind O-antigen, a target dis-
tal on the LPS molecule, and exert their inhibitory effect ei-
ther by activating and depositing complement away from the 
bacterial membrane and preventing MAC insertion or by block-
ing access of protective antibody (Brown et al., 1983; Moffitt 
and Frank, 1994; MacLennan et al., 2010). However, we have 
yet to establish whether low titers of anti–O-antigen IgG2 
can promote bacterial killing without the addition of other 
Figure 8. Inhibitory IgG2 antibody is associated with poor lung 
function. (A) Comparison of FEV1% predicted values for patients from 
two non-CF bronchiectasis cohorts that are colonized with P. aeruginosa 
and display inhibition of serum mediated killing (), patients who are 
colonized with P. aeruginosa and display normal serum-mediated killing 
(), or patients who are not colonized with P. aeruginosa (). The hori-
zontal bars represent the median for each group. FEV1% scores represent 
mean of three independent measurements. *, P < 0.05; **, P < 0.01.
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envelopes from the cytoplasm, after French pressure lysis of bacterial cells, by 
centrifugation (48,000 g for 60 min at 4°C). The envelopes were retained and 
were resuspended in 3 ml of buffer (2% [vol/vol] Triton X-100, 10 mM Tris-
HCl, pH 7.5) and incubated at 25°C for 15 min to solubilize inner mem-
brane components. Triton X-100–extracted envelopes were harvested by 
centrifugation at 48,000 g for 60 min at 4°C and washed four times in 30 ml 
of 10 mM Tris-HCl, pH 7.5. Insoluble fractions were resuspended in 1 ml 
10 mM Tris-HCl pH 7.5 and stored at 20°C.
LPS was isolated as previously described (Browning et al., 2003). In 
brief, Pseudomonas was grown overnight at 37°C. The equivalent of 1 ml of 
OD600 = 1 culture was spun and the pellet resuspended in 100 µl of lysing 
buffer (1 M Tris, pH 6.8, 2% SDS, and 4% 2-mercaptoethanol). The suspen-
sion was then boiled for 10 min, spun down, and supernatant was moved to 
a fresh Eppendorf. 5 µl of 5 mg/ml Proteinase K was added to each sample 
before incubation at 60°C for 1 h. Finally, the LPS preparation was heated at 
98°C for 10 min and stored at 20°C. LPS isolations were quantified by 
running the sample on an SDS-PAGE gel and comparing to five standards 
(10, 5, 1, 0.5, and 0.1 mg/ml) of commercially available Pseudomonas aerugi-
nosa serotype 10 LPS (Sigma-Aldrich).
Bacterial cell fractions were visualized using SilverQuest kit (Invitrogen) 
or Western blotting (Raghunathan et al., 2011) using patient serum (1:200) 
and secondary antibody (1:5,000 alkaline phosphatase conjugated anti–human 
IgG, IgM or IgA; Sigma-Aldrich) before detection with nitro-blue tetrazolium 
and 5-bromo-4-chloro-3-indolyphosphate as the substrate.
Statistical methods. All experiments were performed at least three times 
unless otherwise stated. Correlation was determined using Spearman’s rank 
and Pearson product-moment correlation coefficients. Statistical significance 
between patient groups was determined by Student’s t test. Error bars repre-
sent ± 1 standard error.
Online supplemental material. Fig. S1 gives an overview of all experiments 
performed with S1 serum and a summary of their results. Table S1 lists affin-
ity of Protein A and Protein G for human immunoglobulins. Online sup-
plemental material is available at http://www.jem.org/cgi/content/full/ 
jem.20132444/DC1.
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